| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 112 | 2024 | 1385 | 13.600 |
Why?
|
| Ovarian Neoplasms | 205 | 2024 | 4796 | 11.870 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 44 | 2020 | 481 | 8.340 |
Why?
|
| Carcinoma, Endometrioid | 25 | 2020 | 327 | 4.400 |
Why?
|
| Genes, BRCA1 | 29 | 2023 | 397 | 4.010 |
Why?
|
| Cystadenocarcinoma, Serous | 37 | 2022 | 499 | 3.870 |
Why?
|
| Genes, BRCA2 | 26 | 2020 | 322 | 3.790 |
Why?
|
| Neoplasms, Glandular and Epithelial | 29 | 2022 | 517 | 3.260 |
Why?
|
| CA-125 Antigen | 25 | 2024 | 229 | 3.250 |
Why?
|
| Genetic Testing | 30 | 2024 | 1693 | 2.960 |
Why?
|
| Genetic Predisposition to Disease | 64 | 2024 | 5775 | 2.720 |
Why?
|
| Ovariectomy | 21 | 2023 | 372 | 2.600 |
Why?
|
| Salpingectomy | 10 | 2023 | 46 | 2.550 |
Why?
|
| Metformin | 8 | 2019 | 396 | 2.500 |
Why?
|
| Genetic Counseling | 22 | 2024 | 417 | 2.490 |
Why?
|
| Obesity | 21 | 2020 | 2901 | 2.340 |
Why?
|
| Genital Neoplasms, Female | 18 | 2024 | 794 | 2.330 |
Why?
|
| Endometrial Hyperplasia | 11 | 2024 | 122 | 2.290 |
Why?
|
| Female | 380 | 2024 | 149013 | 2.150 |
Why?
|
| BRCA2 Protein | 20 | 2020 | 380 | 2.130 |
Why?
|
| Endometrium | 14 | 2020 | 457 | 2.120 |
Why?
|
| Germ-Line Mutation | 21 | 2024 | 1101 | 2.080 |
Why?
|
| BRCA1 Protein | 18 | 2023 | 528 | 2.040 |
Why?
|
| Uterine Neoplasms | 18 | 2022 | 575 | 2.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 12 | 2019 | 176 | 1.940 |
Why?
|
| PTEN Phosphohydrolase | 13 | 2016 | 1011 | 1.780 |
Why?
|
| Early Detection of Cancer | 27 | 2024 | 1343 | 1.730 |
Why?
|
| Hysterectomy | 17 | 2023 | 654 | 1.690 |
Why?
|
| Humans | 395 | 2024 | 270884 | 1.550 |
Why?
|
| Biomarkers, Tumor | 53 | 2024 | 10713 | 1.510 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 5 | 2017 | 107 | 1.430 |
Why?
|
| Fallopian Tube Neoplasms | 9 | 2022 | 155 | 1.380 |
Why?
|
| Middle Aged | 195 | 2024 | 90457 | 1.380 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 4 | 2017 | 26 | 1.350 |
Why?
|
| Polymorphism, Single Nucleotide | 35 | 2022 | 4644 | 1.280 |
Why?
|
| Buffaloes | 3 | 2016 | 4 | 1.240 |
Why?
|
| Carcinosarcoma | 7 | 2021 | 145 | 1.180 |
Why?
|
| Adult | 153 | 2024 | 82131 | 1.130 |
Why?
|
| Mutation | 48 | 2024 | 15873 | 1.130 |
Why?
|
| Hypoglycemic Agents | 3 | 2016 | 600 | 1.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 31 | 2020 | 9042 | 1.110 |
Why?
|
| Aged | 144 | 2024 | 73436 | 1.070 |
Why?
|
| Cystadenocarcinoma, Papillary | 8 | 2006 | 82 | 1.070 |
Why?
|
| DNA Mismatch Repair | 8 | 2020 | 283 | 1.060 |
Why?
|
| Salpingo-oophorectomy | 5 | 2023 | 50 | 1.040 |
Why?
|
| Neoplasms, Multiple Primary | 10 | 2014 | 557 | 1.030 |
Why?
|
| Peritoneal Neoplasms | 11 | 2024 | 863 | 1.020 |
Why?
|
| Breast Neoplasms | 39 | 2024 | 16238 | 1.000 |
Why?
|
| Oocytes | 3 | 2016 | 413 | 0.960 |
Why?
|
| Heterozygote | 16 | 2022 | 1057 | 0.920 |
Why?
|
| Neoplasm Staging | 55 | 2024 | 14020 | 0.920 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2014 | 1235 | 0.900 |
Why?
|
| Rosaniline Dyes | 1 | 2023 | 109 | 0.880 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2013 | 841 | 0.820 |
Why?
|
| Body Mass Index | 17 | 2020 | 2230 | 0.820 |
Why?
|
| Aged, 80 and over | 67 | 2023 | 31029 | 0.780 |
Why?
|
| Risk | 15 | 2018 | 1937 | 0.760 |
Why?
|
| Adiponectin | 4 | 2016 | 143 | 0.760 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 7 | 2023 | 521 | 0.760 |
Why?
|
| Risk Factors | 48 | 2022 | 17897 | 0.740 |
Why?
|
| Neoplastic Syndromes, Hereditary | 5 | 2021 | 232 | 0.710 |
Why?
|
| Estradiol | 4 | 2017 | 828 | 0.690 |
Why?
|
| Cytoreduction Surgical Procedures | 9 | 2021 | 510 | 0.690 |
Why?
|
| Case-Control Studies | 30 | 2024 | 6230 | 0.690 |
Why?
|
| Medical History Taking | 4 | 2014 | 175 | 0.680 |
Why?
|
| Premenopause | 6 | 2020 | 136 | 0.670 |
Why?
|
| Mass Screening | 13 | 2024 | 1553 | 0.670 |
Why?
|
| Neoplasm Recurrence, Local | 24 | 2024 | 10401 | 0.660 |
Why?
|
| Cell Proliferation | 18 | 2021 | 7221 | 0.660 |
Why?
|
| Swine, Miniature | 2 | 2016 | 71 | 0.660 |
Why?
|
| Uterine Hemorrhage | 2 | 2016 | 64 | 0.660 |
Why?
|
| Prospective Studies | 25 | 2024 | 13436 | 0.650 |
Why?
|
| DNA Repair Enzymes | 4 | 2015 | 238 | 0.650 |
Why?
|
| Protein Kinases | 3 | 2008 | 891 | 0.640 |
Why?
|
| Uterine Cervical Neoplasms | 10 | 2024 | 1903 | 0.640 |
Why?
|
| Telephone | 1 | 2019 | 160 | 0.630 |
Why?
|
| Health Services Accessibility | 4 | 2019 | 831 | 0.630 |
Why?
|
| Pylorus | 1 | 2018 | 31 | 0.620 |
Why?
|
| Sirolimus | 7 | 2016 | 829 | 0.620 |
Why?
|
| Adenosine Triphosphatases | 4 | 2015 | 426 | 0.610 |
Why?
|
| Body Weight | 3 | 2019 | 1296 | 0.600 |
Why?
|
| Healthy Lifestyle | 1 | 2018 | 42 | 0.600 |
Why?
|
| Tamoxifen | 4 | 2017 | 873 | 0.600 |
Why?
|
| Gastric Emptying | 1 | 2018 | 99 | 0.600 |
Why?
|
| Contraceptives, Oral | 3 | 2013 | 57 | 0.600 |
Why?
|
| Spermatozoa | 2 | 2011 | 288 | 0.590 |
Why?
|
| Immunohistochemistry | 27 | 2018 | 7636 | 0.590 |
Why?
|
| Lynch Syndrome II | 1 | 2017 | 3 | 0.590 |
Why?
|
| Genetic Services | 1 | 2017 | 11 | 0.580 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 7 | 2024 | 1402 | 0.580 |
Why?
|
| Attitude to Health | 3 | 2019 | 434 | 0.570 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2017 | 46 | 0.570 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2018 | 63 | 0.570 |
Why?
|
| Weight Reduction Programs | 1 | 2018 | 74 | 0.570 |
Why?
|
| Intrauterine Devices, Medicated | 3 | 2024 | 38 | 0.560 |
Why?
|
| Genome-Wide Association Study | 16 | 2020 | 2351 | 0.560 |
Why?
|
| Levonorgestrel | 3 | 2024 | 53 | 0.550 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2017 | 161 | 0.540 |
Why?
|
| Cytochalasin B | 1 | 2016 | 15 | 0.540 |
Why?
|
| Cryoprotective Agents | 1 | 2016 | 9 | 0.540 |
Why?
|
| Exercise | 5 | 2019 | 1185 | 0.530 |
Why?
|
| Cloning, Organism | 1 | 2015 | 6 | 0.530 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2015 | 6 | 0.530 |
Why?
|
| Sentinel Lymph Node | 3 | 2019 | 241 | 0.530 |
Why?
|
| Gene Expression | 7 | 2020 | 3618 | 0.530 |
Why?
|
| Postmenopause | 6 | 2022 | 375 | 0.530 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2016 | 24 | 0.520 |
Why?
|
| DNA-Binding Proteins | 15 | 2024 | 4979 | 0.520 |
Why?
|
| DNA Methylation | 12 | 2020 | 2769 | 0.510 |
Why?
|
| Spermatogonia | 1 | 2016 | 101 | 0.510 |
Why?
|
| RNA, Messenger | 16 | 2016 | 6353 | 0.500 |
Why?
|
| Receptors, Progesterone | 8 | 2017 | 1610 | 0.500 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2023 | 1387 | 0.500 |
Why?
|
| Cryopreservation | 1 | 2016 | 151 | 0.500 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2015 | 165 | 0.500 |
Why?
|
| TOR Serine-Threonine Kinases | 12 | 2016 | 1537 | 0.490 |
Why?
|
| Prognosis | 41 | 2024 | 22522 | 0.480 |
Why?
|
| Estrogen Receptor alpha | 3 | 2017 | 692 | 0.480 |
Why?
|
| Internet | 1 | 2019 | 689 | 0.480 |
Why?
|
| Neoplasm Proteins | 11 | 2018 | 3345 | 0.480 |
Why?
|
| Neoplasm Grading | 14 | 2021 | 1824 | 0.480 |
Why?
|
| ras Proteins | 4 | 2024 | 801 | 0.470 |
Why?
|
| Preimplantation Diagnosis | 2 | 2014 | 37 | 0.470 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2017 | 49 | 0.470 |
Why?
|
| Cost-Benefit Analysis | 10 | 2021 | 968 | 0.460 |
Why?
|
| Neoplasms | 14 | 2024 | 15933 | 0.460 |
Why?
|
| Genotype | 18 | 2018 | 4248 | 0.460 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2017 | 602 | 0.460 |
Why?
|
| Membrane Proteins | 9 | 2021 | 2911 | 0.460 |
Why?
|
| Bayes Theorem | 8 | 2024 | 1060 | 0.460 |
Why?
|
| Animals | 42 | 2024 | 61671 | 0.450 |
Why?
|
| Chickens | 2 | 2017 | 781 | 0.450 |
Why?
|
| Retrospective Studies | 49 | 2024 | 39940 | 0.450 |
Why?
|
| Quality of Life | 15 | 2024 | 4779 | 0.450 |
Why?
|
| Mixed Tumor, Mullerian | 3 | 2015 | 37 | 0.450 |
Why?
|
| Neoplasms, Second Primary | 6 | 2010 | 1388 | 0.450 |
Why?
|
| Estrogens | 3 | 2020 | 807 | 0.450 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2013 | 30 | 0.440 |
Why?
|
| Jews | 3 | 2015 | 57 | 0.440 |
Why?
|
| Physical Fitness | 1 | 2014 | 124 | 0.440 |
Why?
|
| Cohort Studies | 23 | 2021 | 9469 | 0.440 |
Why?
|
| Gynecology | 3 | 2017 | 235 | 0.440 |
Why?
|
| Fallopian Tubes | 5 | 2019 | 129 | 0.430 |
Why?
|
| Insulin Resistance | 2 | 2011 | 726 | 0.430 |
Why?
|
| Quality Improvement | 4 | 2023 | 914 | 0.430 |
Why?
|
| Risk Reduction Behavior | 5 | 2018 | 208 | 0.430 |
Why?
|
| Streptozocin | 1 | 2013 | 70 | 0.420 |
Why?
|
| Antineoplastic Agents | 26 | 2023 | 14631 | 0.420 |
Why?
|
| Hyperinsulinism | 1 | 2013 | 85 | 0.420 |
Why?
|
| Gynecologic Surgical Procedures | 4 | 2021 | 381 | 0.420 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2020 | 1464 | 0.410 |
Why?
|
| Medical Oncology | 5 | 2023 | 1464 | 0.410 |
Why?
|
| Young Adult | 27 | 2023 | 22286 | 0.410 |
Why?
|
| Surgical Flaps | 7 | 2001 | 894 | 0.400 |
Why?
|
| Proto-Oncogene Proteins c-akt | 11 | 2022 | 2056 | 0.400 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2016 | 299 | 0.400 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2020 | 4006 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2023 | 16722 | 0.390 |
Why?
|
| Sex Preselection | 1 | 2011 | 8 | 0.390 |
Why?
|
| Risk Assessment | 16 | 2020 | 6763 | 0.390 |
Why?
|
| Microsatellite Instability | 8 | 2020 | 408 | 0.380 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 1275 | 0.380 |
Why?
|
| Exercise Therapy | 1 | 2014 | 277 | 0.380 |
Why?
|
| Genetic Loci | 4 | 2017 | 501 | 0.380 |
Why?
|
| Autoantibodies | 4 | 2024 | 606 | 0.370 |
Why?
|
| Melatonin | 1 | 2011 | 53 | 0.370 |
Why?
|
| Ovary | 12 | 2023 | 687 | 0.370 |
Why?
|
| Cell Line, Tumor | 25 | 2021 | 14875 | 0.370 |
Why?
|
| Omentum | 3 | 2020 | 108 | 0.370 |
Why?
|
| Genetic Variation | 6 | 2019 | 2164 | 0.370 |
Why?
|
| MutS Homolog 2 Protein | 6 | 2014 | 179 | 0.370 |
Why?
|
| Progestins | 2 | 2010 | 92 | 0.370 |
Why?
|
| Phosphatidylinositol 3-Kinases | 10 | 2021 | 1712 | 0.370 |
Why?
|
| Adenocarcinoma | 10 | 2018 | 7917 | 0.370 |
Why?
|
| Carbon Monoxide | 1 | 2010 | 67 | 0.360 |
Why?
|
| Vehicle Emissions | 1 | 2010 | 25 | 0.360 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 13 | 2014 | 3585 | 0.360 |
Why?
|
| Environmental Monitoring | 1 | 2010 | 104 | 0.350 |
Why?
|
| Survivors | 4 | 2017 | 1019 | 0.350 |
Why?
|
| Epididymal Secretory Proteins | 3 | 2010 | 15 | 0.350 |
Why?
|
| Genetic Association Studies | 10 | 2019 | 1098 | 0.350 |
Why?
|
| Carcinoma | 7 | 2018 | 2610 | 0.350 |
Why?
|
| Particulate Matter | 1 | 2010 | 86 | 0.350 |
Why?
|
| Gene Amplification | 5 | 2017 | 765 | 0.340 |
Why?
|
| Stem Cells | 1 | 2016 | 1213 | 0.340 |
Why?
|
| Colorectal Neoplasms | 9 | 2024 | 3707 | 0.330 |
Why?
|
| Carcinoma, Papillary | 4 | 2006 | 566 | 0.330 |
Why?
|
| Macaca | 1 | 2009 | 88 | 0.330 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2009 | 38 | 0.330 |
Why?
|
| United States | 23 | 2024 | 15887 | 0.330 |
Why?
|
| Alleles | 10 | 2019 | 2593 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2016 | 1897 | 0.330 |
Why?
|
| Everolimus | 6 | 2021 | 436 | 0.320 |
Why?
|
| Air Pollutants | 1 | 2010 | 135 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2014 | 2605 | 0.320 |
Why?
|
| Gene Expression Profiling | 19 | 2020 | 5143 | 0.320 |
Why?
|
| Cumulus Cells | 1 | 2008 | 44 | 0.310 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2008 | 24 | 0.310 |
Why?
|
| MutL Protein Homolog 1 | 6 | 2014 | 206 | 0.310 |
Why?
|
| Lectins | 2 | 2020 | 147 | 0.310 |
Why?
|
| Oocyte Retrieval | 1 | 2008 | 8 | 0.310 |
Why?
|
| Ultrasonography | 6 | 2024 | 1935 | 0.310 |
Why?
|
| Rats, Zucker | 3 | 2014 | 59 | 0.310 |
Why?
|
| Promoter Regions, Genetic | 7 | 2020 | 3175 | 0.300 |
Why?
|
| Quantitative Trait Loci | 7 | 2020 | 384 | 0.300 |
Why?
|
| Apoptosis | 10 | 2016 | 7747 | 0.300 |
Why?
|
| Referral and Consultation | 4 | 2016 | 931 | 0.300 |
Why?
|
| Odds Ratio | 9 | 2018 | 2310 | 0.300 |
Why?
|
| Sensitivity and Specificity | 14 | 2024 | 5161 | 0.300 |
Why?
|
| Markov Chains | 4 | 2024 | 188 | 0.300 |
Why?
|
| Logistic Models | 12 | 2018 | 3443 | 0.300 |
Why?
|
| Rats | 8 | 2021 | 6430 | 0.300 |
Why?
|
| Swine | 5 | 2016 | 1534 | 0.290 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2017 | 3654 | 0.290 |
Why?
|
| Genes | 1 | 2009 | 603 | 0.290 |
Why?
|
| Obstetrics | 1 | 2010 | 243 | 0.290 |
Why?
|
| Pregnancy, Animal | 1 | 2008 | 102 | 0.290 |
Why?
|
| Leukemia | 1 | 2016 | 1719 | 0.290 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 147 | 0.280 |
Why?
|
| Anticarcinogenic Agents | 2 | 2014 | 368 | 0.280 |
Why?
|
| Age of Onset | 4 | 2020 | 852 | 0.280 |
Why?
|
| Cocarcinogenesis | 1 | 2007 | 56 | 0.280 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2020 | 1462 | 0.280 |
Why?
|
| PPAR gamma | 1 | 2008 | 224 | 0.280 |
Why?
|
| Signal Transduction | 14 | 2019 | 12056 | 0.280 |
Why?
|
| Salpingostomy | 1 | 2006 | 8 | 0.280 |
Why?
|
| Disease-Free Survival | 19 | 2021 | 10266 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2007 | 142 | 0.280 |
Why?
|
| GPI-Linked Proteins | 5 | 2020 | 233 | 0.280 |
Why?
|
| Postoperative Complications | 8 | 2024 | 5679 | 0.270 |
Why?
|
| Maintenance Chemotherapy | 2 | 2019 | 226 | 0.270 |
Why?
|
| Treatment Outcome | 30 | 2022 | 33775 | 0.270 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2020 | 2272 | 0.270 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 4 | 2015 | 49 | 0.270 |
Why?
|
| Disease Models, Animal | 6 | 2020 | 7365 | 0.270 |
Why?
|
| Receptors, Guanylate Cyclase-Coupled | 1 | 2006 | 2 | 0.270 |
Why?
|
| Fertilization in Vitro | 1 | 2008 | 207 | 0.270 |
Why?
|
| Tephritidae | 1 | 2006 | 2 | 0.270 |
Why?
|
| Receptors, Estrogen | 5 | 2015 | 2177 | 0.270 |
Why?
|
| Program Evaluation | 3 | 2022 | 603 | 0.270 |
Why?
|
| Intra-Abdominal Fat | 2 | 2018 | 94 | 0.270 |
Why?
|
| Terminal Care | 1 | 2011 | 466 | 0.270 |
Why?
|
| Adiposity | 2 | 2018 | 238 | 0.260 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2019 | 442 | 0.260 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2018 | 624 | 0.260 |
Why?
|
| Immunoenzyme Techniques | 5 | 2014 | 1187 | 0.260 |
Why?
|
| Hysterectomy, Vaginal | 2 | 2017 | 35 | 0.260 |
Why?
|
| Nuclear Proteins | 8 | 2016 | 3423 | 0.260 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2016 | 131 | 0.260 |
Why?
|
| Patient Outcome Assessment | 2 | 2019 | 245 | 0.260 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2016 | 1303 | 0.260 |
Why?
|
| Adipose Tissue | 3 | 2016 | 706 | 0.250 |
Why?
|
| Survival Rate | 17 | 2020 | 12538 | 0.250 |
Why?
|
| Cyclins | 2 | 2006 | 463 | 0.250 |
Why?
|
| Fertility | 2 | 2005 | 335 | 0.250 |
Why?
|
| Pilot Projects | 8 | 2021 | 2828 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2021 | 6257 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2019 | 1523 | 0.250 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2019 | 562 | 0.240 |
Why?
|
| Surveys and Questionnaires | 13 | 2022 | 5930 | 0.240 |
Why?
|
| Germinoma | 1 | 2005 | 82 | 0.240 |
Why?
|
| Algorithms | 10 | 2022 | 3889 | 0.240 |
Why?
|
| Proteins | 5 | 2022 | 2034 | 0.240 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2008 | 484 | 0.240 |
Why?
|
| Oxidative Stress | 1 | 2011 | 1150 | 0.240 |
Why?
|
| Piperazines | 6 | 2021 | 2145 | 0.240 |
Why?
|
| Pedigree | 5 | 2014 | 2034 | 0.240 |
Why?
|
| Cyclin D1 | 2 | 2006 | 589 | 0.240 |
Why?
|
| Skin | 4 | 2001 | 1266 | 0.240 |
Why?
|
| Precancerous Conditions | 3 | 2024 | 1059 | 0.240 |
Why?
|
| Time Factors | 12 | 2024 | 13000 | 0.240 |
Why?
|
| Gene Deletion | 3 | 2015 | 1468 | 0.240 |
Why?
|
| Cobalt | 1 | 2024 | 57 | 0.230 |
Why?
|
| Progesterone | 1 | 2007 | 711 | 0.230 |
Why?
|
| Biomarkers | 6 | 2020 | 5049 | 0.230 |
Why?
|
| Titanium | 1 | 2024 | 62 | 0.230 |
Why?
|
| Computer Simulation | 4 | 2018 | 1572 | 0.230 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2024 | 60 | 0.230 |
Why?
|
| Genomics | 5 | 2024 | 2834 | 0.230 |
Why?
|
| Surface Properties | 1 | 2024 | 189 | 0.230 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 111 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2004 | 156 | 0.220 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 227 | 0.220 |
Why?
|
| Microsatellite Repeats | 5 | 2017 | 627 | 0.220 |
Why?
|
| Transcription Factors | 6 | 2024 | 5399 | 0.220 |
Why?
|
| Lymph Node Excision | 5 | 2020 | 2068 | 0.220 |
Why?
|
| Parity | 3 | 2011 | 135 | 0.220 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2022 | 1836 | 0.220 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 4095 | 0.220 |
Why?
|
| Ascites | 4 | 2023 | 213 | 0.220 |
Why?
|
| cdc25 Phosphatases | 1 | 2003 | 101 | 0.220 |
Why?
|
| MicroRNAs | 3 | 2021 | 2883 | 0.220 |
Why?
|
| Paclitaxel | 7 | 2019 | 2105 | 0.220 |
Why?
|
| Copper | 1 | 2024 | 165 | 0.210 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 4963 | 0.210 |
Why?
|
| Medically Underserved Area | 1 | 2024 | 123 | 0.210 |
Why?
|
| Immunoassay | 3 | 2014 | 214 | 0.210 |
Why?
|
| Blood Proteins | 2 | 2019 | 299 | 0.210 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2014 | 226 | 0.210 |
Why?
|
| Cyclin E | 4 | 2022 | 283 | 0.210 |
Why?
|
| Health Behavior | 2 | 2019 | 601 | 0.210 |
Why?
|
| Combined Modality Therapy | 9 | 2020 | 9038 | 0.200 |
Why?
|
| Pyrimidines | 5 | 2021 | 3671 | 0.200 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2018 | 105 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 12 | 2015 | 2477 | 0.200 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2019 | 881 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 9 | 2020 | 4051 | 0.200 |
Why?
|
| Physicians | 1 | 2010 | 854 | 0.200 |
Why?
|
| Oncogenes | 3 | 2016 | 699 | 0.200 |
Why?
|
| Counseling | 2 | 2023 | 383 | 0.200 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 919 | 0.200 |
Why?
|
| Mice | 16 | 2022 | 35449 | 0.200 |
Why?
|
| Advance Care Planning | 1 | 2023 | 93 | 0.200 |
Why?
|
| Age Factors | 9 | 2018 | 5453 | 0.200 |
Why?
|
| Adolescent | 24 | 2019 | 32778 | 0.200 |
Why?
|
| Colon | 1 | 2005 | 658 | 0.190 |
Why?
|
| Enzyme Inhibitors | 3 | 2008 | 1943 | 0.190 |
Why?
|
| Primary Prevention | 3 | 2023 | 232 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2022 | 877 | 0.190 |
Why?
|
| ROC Curve | 8 | 2024 | 1251 | 0.190 |
Why?
|
| Cost Sharing | 1 | 2021 | 7 | 0.190 |
Why?
|
| Cell Cycle Proteins | 4 | 2022 | 2105 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2024 | 2450 | 0.190 |
Why?
|
| Ascitic Fluid | 1 | 2021 | 84 | 0.190 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 657 | 0.190 |
Why?
|
| Schools | 1 | 2022 | 237 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1410 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2018 | 694 | 0.180 |
Why?
|
| Male | 32 | 2020 | 128379 | 0.180 |
Why?
|
| Vaginal Neoplasms | 1 | 2021 | 152 | 0.180 |
Why?
|
| Cells, Cultured | 5 | 2024 | 5677 | 0.180 |
Why?
|
| Health Care Costs | 4 | 2019 | 699 | 0.180 |
Why?
|
| Fatigue | 4 | 2018 | 1278 | 0.180 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 489 | 0.180 |
Why?
|
| Health Expenditures | 2 | 2021 | 202 | 0.180 |
Why?
|
| Survival Analysis | 12 | 2020 | 9290 | 0.180 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 519 | 0.180 |
Why?
|
| Vagina | 1 | 2022 | 331 | 0.180 |
Why?
|
| beta Catenin | 4 | 2015 | 682 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2018 | 1566 | 0.180 |
Why?
|
| Quality Indicators, Health Care | 2 | 2014 | 354 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 2 | 2019 | 1097 | 0.180 |
Why?
|
| Epithelial Cells | 5 | 2007 | 1863 | 0.180 |
Why?
|
| Stromal Cells | 2 | 2016 | 823 | 0.180 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2022 | 240 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-abl | 3 | 2005 | 84 | 0.170 |
Why?
|
| Laparoscopy | 5 | 2021 | 1304 | 0.170 |
Why?
|
| Proto-Oncogenes | 2 | 2013 | 208 | 0.170 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 4328 | 0.170 |
Why?
|
| Follow-Up Studies | 16 | 2024 | 15267 | 0.170 |
Why?
|
| Ki-67 Antigen | 3 | 2020 | 675 | 0.170 |
Why?
|
| Embryonic Development | 2 | 2015 | 310 | 0.170 |
Why?
|
| Chemoprevention | 4 | 2014 | 251 | 0.170 |
Why?
|
| Neoplasm, Residual | 2 | 2023 | 1761 | 0.170 |
Why?
|
| Cyclopentanes | 1 | 2020 | 42 | 0.170 |
Why?
|
| Homologous Recombination | 1 | 2021 | 188 | 0.170 |
Why?
|
| Skin Transplantation | 2 | 2000 | 186 | 0.170 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 1464 | 0.170 |
Why?
|
| Monte Carlo Method | 4 | 2011 | 709 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 1468 | 0.170 |
Why?
|
| Pregnancy | 10 | 2018 | 8122 | 0.170 |
Why?
|
| Carrier Proteins | 4 | 2015 | 2082 | 0.170 |
Why?
|
| Cytokines | 2 | 2020 | 2830 | 0.170 |
Why?
|
| Life Style | 2 | 2021 | 618 | 0.170 |
Why?
|
| DNA Repair | 4 | 2008 | 1906 | 0.160 |
Why?
|
| RNA, Long Noncoding | 2 | 2015 | 613 | 0.160 |
Why?
|
| Insulin | 2 | 2016 | 1432 | 0.160 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2015 | 1002 | 0.160 |
Why?
|
| Cisplatin | 4 | 2019 | 2500 | 0.160 |
Why?
|
| Internship and Residency | 1 | 2010 | 1454 | 0.160 |
Why?
|
| Membrane Glycoproteins | 4 | 2008 | 1096 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 134 | 0.160 |
Why?
|
| Energy Intake | 2 | 2019 | 518 | 0.160 |
Why?
|
| Leg Injuries | 1 | 1999 | 29 | 0.160 |
Why?
|
| Drug Delivery Systems | 2 | 2021 | 660 | 0.160 |
Why?
|
| Placenta Growth Factor | 1 | 2018 | 26 | 0.160 |
Why?
|
| Incidence | 6 | 2021 | 5830 | 0.160 |
Why?
|
| Receptor, ErbB-2 | 2 | 2012 | 2658 | 0.160 |
Why?
|
| Cetuximab | 1 | 2020 | 474 | 0.160 |
Why?
|
| SEER Program | 5 | 2024 | 1052 | 0.160 |
Why?
|
| Rho Guanine Nucleotide Exchange Factors | 1 | 2018 | 27 | 0.160 |
Why?
|
| Lymphatic Metastasis | 5 | 2021 | 4969 | 0.160 |
Why?
|
| Prostatic Neoplasms | 5 | 2016 | 5867 | 0.160 |
Why?
|
| Phthalazines | 3 | 2021 | 262 | 0.160 |
Why?
|
| Thymidylate Synthase | 1 | 2018 | 57 | 0.160 |
Why?
|
| RNA, Antisense | 1 | 2018 | 78 | 0.160 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2018 | 45 | 0.160 |
Why?
|
| Phenotype | 5 | 2022 | 6484 | 0.150 |
Why?
|
| A Kinase Anchor Proteins | 1 | 2018 | 25 | 0.150 |
Why?
|
| Fibroblasts | 3 | 2016 | 1646 | 0.150 |
Why?
|
| Protein Kinase C | 2 | 2013 | 407 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2005 | 483 | 0.150 |
Why?
|
| Disease Progression | 9 | 2018 | 6869 | 0.150 |
Why?
|
| Family | 3 | 2020 | 782 | 0.150 |
Why?
|
| Pain, Postoperative | 2 | 2021 | 662 | 0.150 |
Why?
|
| Coloring Agents | 2 | 2017 | 232 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 275 | 0.150 |
Why?
|
| Drug Approval | 1 | 2019 | 175 | 0.150 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 81 | 0.150 |
Why?
|
| Leptin | 2 | 2016 | 305 | 0.150 |
Why?
|
| Phosphorylation | 6 | 2012 | 4911 | 0.150 |
Why?
|
| Gastrointestinal Motility | 1 | 2018 | 85 | 0.150 |
Why?
|
| Cell Movement | 5 | 2021 | 2472 | 0.150 |
Why?
|
| Transcription Factor TFIID | 1 | 2017 | 27 | 0.140 |
Why?
|
| Heredity | 2 | 2014 | 26 | 0.140 |
Why?
|
| Weight Loss | 2 | 2019 | 628 | 0.140 |
Why?
|
| TATA-Binding Protein Associated Factors | 1 | 2017 | 27 | 0.140 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2019 | 116 | 0.140 |
Why?
|
| Neoadjuvant Therapy | 6 | 2021 | 5238 | 0.140 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2017 | 78 | 0.140 |
Why?
|
| Chick Embryo | 1 | 2017 | 217 | 0.140 |
Why?
|
| Loss of Heterozygosity | 3 | 2012 | 623 | 0.140 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 5102 | 0.140 |
Why?
|
| Body Height | 1 | 2018 | 234 | 0.140 |
Why?
|
| Population Surveillance | 3 | 2019 | 647 | 0.140 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2015 | 162 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 206 | 0.140 |
Why?
|
| Cell Aggregation | 1 | 2016 | 61 | 0.140 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2015 | 373 | 0.140 |
Why?
|
| Decision Support Techniques | 3 | 2019 | 603 | 0.140 |
Why?
|
| Vaginal Discharge | 1 | 2016 | 9 | 0.140 |
Why?
|
| Trans-Activators | 1 | 2003 | 1618 | 0.140 |
Why?
|
| Patient Selection | 2 | 2017 | 2030 | 0.140 |
Why?
|
| Health Surveys | 3 | 2019 | 400 | 0.140 |
Why?
|
| Health Status Disparities | 2 | 2020 | 322 | 0.140 |
Why?
|
| Vitrification | 1 | 2016 | 6 | 0.140 |
Why?
|
| Patient Preference | 1 | 2019 | 231 | 0.130 |
Why?
|
| Purpura | 1 | 2016 | 35 | 0.130 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2016 | 42 | 0.130 |
Why?
|
| Indocyanine Green | 1 | 2017 | 125 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2023 | 3414 | 0.130 |
Why?
|
| RNA Editing | 1 | 2016 | 97 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2016 | 155 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 2 | 2020 | 442 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2021 | 698 | 0.130 |
Why?
|
| Neutropenia | 3 | 2016 | 1005 | 0.130 |
Why?
|
| Proteome | 1 | 2020 | 570 | 0.130 |
Why?
|
| Animals, Genetically Modified | 2 | 2015 | 393 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 1439 | 0.130 |
Why?
|
| Reproductive Health | 1 | 2016 | 49 | 0.130 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 3043 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 237 | 0.130 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2016 | 37 | 0.130 |
Why?
|
| Codon, Terminator | 1 | 2015 | 43 | 0.130 |
Why?
|
| Polycomb-Group Proteins | 1 | 2015 | 42 | 0.130 |
Why?
|
| Folic Acid | 2 | 2019 | 371 | 0.130 |
Why?
|
| Actin Cytoskeleton | 1 | 2016 | 78 | 0.130 |
Why?
|
| Leukocytosis | 1 | 2016 | 123 | 0.130 |
Why?
|
| Oogenesis | 1 | 2016 | 74 | 0.130 |
Why?
|
| Transfection | 5 | 2010 | 3107 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 273 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 484 | 0.130 |
Why?
|
| Blastocyst | 1 | 2016 | 138 | 0.130 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 2057 | 0.130 |
Why?
|
| Meta-Analysis as Topic | 4 | 2017 | 274 | 0.130 |
Why?
|
| Tubulin | 1 | 2016 | 202 | 0.130 |
Why?
|
| Meiosis | 1 | 2016 | 173 | 0.130 |
Why?
|
| Ideal Body Weight | 1 | 2015 | 8 | 0.130 |
Why?
|
| Testis | 2 | 2016 | 613 | 0.130 |
Why?
|
| Caspase 3 | 1 | 2016 | 473 | 0.130 |
Why?
|
| Risk Management | 2 | 2019 | 112 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 2402 | 0.130 |
Why?
|
| Colonoscopy | 3 | 2014 | 522 | 0.130 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2016 | 221 | 0.130 |
Why?
|
| Endometriosis | 2 | 2015 | 231 | 0.130 |
Why?
|
| Genes, bcl-2 | 1 | 2015 | 171 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 873 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2014 | 1336 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 3156 | 0.120 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 907 | 0.120 |
Why?
|
| Thrombocytopenia | 3 | 2016 | 870 | 0.120 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 124 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2017 | 300 | 0.120 |
Why?
|
| Pyrimidinones | 1 | 2017 | 318 | 0.120 |
Why?
|
| Histone Acetyltransferases | 1 | 2017 | 431 | 0.120 |
Why?
|
| rho GTP-Binding Proteins | 2 | 2008 | 180 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1997 | 413 | 0.120 |
Why?
|
| Hyperplasia | 2 | 2014 | 560 | 0.120 |
Why?
|
| Germ Cells | 1 | 2017 | 329 | 0.120 |
Why?
|
| Choice Behavior | 1 | 2016 | 207 | 0.120 |
Why?
|
| Embryo, Mammalian | 2 | 2008 | 735 | 0.120 |
Why?
|
| Telemedicine | 1 | 2021 | 552 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2011 | 1570 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 223 | 0.120 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2014 | 9 | 0.120 |
Why?
|
| Body Composition | 1 | 2018 | 605 | 0.120 |
Why?
|
| Gonadotropins | 1 | 2014 | 52 | 0.120 |
Why?
|
| Cell Line | 3 | 2017 | 5328 | 0.120 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2016 | 211 | 0.120 |
Why?
|
| Microfluidics | 1 | 2014 | 32 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2013 | 1559 | 0.120 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 212 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5581 | 0.120 |
Why?
|
| Surgical Oncology | 1 | 2017 | 211 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2017 | 293 | 0.120 |
Why?
|
| Fertility Preservation | 1 | 2016 | 151 | 0.120 |
Why?
|
| Microtubules | 1 | 2016 | 328 | 0.120 |
Why?
|
| Carboplatin | 4 | 2019 | 880 | 0.120 |
Why?
|
| Cell Separation | 1 | 2016 | 607 | 0.120 |
Why?
|
| Cytoskeleton | 1 | 2016 | 292 | 0.120 |
Why?
|
| Pyridones | 1 | 2017 | 363 | 0.120 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 571 | 0.120 |
Why?
|
| Spermatogenesis | 1 | 2016 | 264 | 0.120 |
Why?
|
| Sleep | 1 | 2018 | 442 | 0.120 |
Why?
|
| Mastectomy | 4 | 2009 | 1553 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 3925 | 0.120 |
Why?
|
| DNA, Neoplasm | 4 | 2015 | 1958 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2011 | 1308 | 0.120 |
Why?
|
| Placenta | 1 | 2018 | 560 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 437 | 0.120 |
Why?
|
| beta-Defensins | 3 | 2010 | 31 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 261 | 0.120 |
Why?
|
| Lysophospholipids | 2 | 2006 | 148 | 0.120 |
Why?
|
| Triazoles | 2 | 2017 | 628 | 0.110 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 233 | 0.110 |
Why?
|
| Health Personnel | 3 | 2017 | 652 | 0.110 |
Why?
|
| Waist Circumference | 1 | 2014 | 100 | 0.110 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 811 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 5 | 2014 | 529 | 0.110 |
Why?
|
| Perception | 2 | 2013 | 349 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1337 | 0.110 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2015 | 204 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2005 | 153 | 0.110 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2014 | 133 | 0.110 |
Why?
|
| Neoplasm Metastasis | 8 | 2019 | 5317 | 0.110 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 394 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2015 | 234 | 0.110 |
Why?
|
| Texas | 7 | 2021 | 6454 | 0.110 |
Why?
|
| Cellular Reprogramming | 1 | 2015 | 200 | 0.110 |
Why?
|
| Genital Diseases, Female | 2 | 2011 | 60 | 0.110 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 628 | 0.110 |
Why?
|
| Interleukin-1alpha | 1 | 2013 | 53 | 0.110 |
Why?
|
| Nitriles | 2 | 2017 | 940 | 0.110 |
Why?
|
| Phosphoproteins | 2 | 2016 | 1130 | 0.110 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2014 | 126 | 0.110 |
Why?
|
| Home Care Services | 1 | 2014 | 99 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 2150 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 249 | 0.110 |
Why?
|
| Communication | 2 | 2024 | 841 | 0.110 |
Why?
|
| Exosomes | 1 | 2016 | 255 | 0.110 |
Why?
|
| Dyspnea | 1 | 2016 | 420 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 1 | 2013 | 138 | 0.110 |
Why?
|
| Fever | 1 | 2016 | 521 | 0.110 |
Why?
|
| Down-Regulation | 5 | 2021 | 2086 | 0.110 |
Why?
|
| Actins | 1 | 2016 | 595 | 0.110 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2013 | 41 | 0.110 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 2 | 2014 | 119 | 0.110 |
Why?
|
| Cell Survival | 4 | 2011 | 3059 | 0.110 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2014 | 143 | 0.110 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2013 | 210 | 0.110 |
Why?
|
| Blotting, Western | 5 | 2012 | 3568 | 0.110 |
Why?
|
| Brachytherapy | 3 | 2020 | 1005 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2019 | 1580 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 884 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2010 | 536 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2012 | 1125 | 0.100 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2014 | 199 | 0.100 |
Why?
|
| Microchip Analytical Procedures | 1 | 2012 | 9 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 464 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 1832 | 0.100 |
Why?
|
| Family Health | 1 | 2013 | 348 | 0.100 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2012 | 25 | 0.100 |
Why?
|
| Bone Regeneration | 1 | 2012 | 35 | 0.100 |
Why?
|
| Registries | 4 | 2015 | 2221 | 0.100 |
Why?
|
| Recombinational DNA Repair | 1 | 2012 | 79 | 0.100 |
Why?
|
| Chromosome Deletion | 1 | 1997 | 1048 | 0.100 |
Why?
|
| Research Design | 2 | 2018 | 1571 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 244 | 0.100 |
Why?
|
| DNA Mutational Analysis | 5 | 2017 | 2356 | 0.100 |
Why?
|
| Fibrin | 1 | 2012 | 81 | 0.100 |
Why?
|
| Models, Biological | 2 | 2018 | 3192 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2019 | 2033 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 5417 | 0.100 |
Why?
|
| Lung Neoplasms | 5 | 2024 | 12039 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2014 | 228 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 376 | 0.100 |
Why?
|
| RNA, Neoplasm | 1 | 2014 | 805 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2015 | 505 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 2657 | 0.100 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2011 | 28 | 0.100 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 6177 | 0.100 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 1310 | 0.100 |
Why?
|
| Haplotypes | 2 | 2011 | 910 | 0.100 |
Why?
|
| Cell Cycle | 2 | 2015 | 2130 | 0.090 |
Why?
|
| Exome | 2 | 2017 | 1248 | 0.090 |
Why?
|
| Protein Transport | 1 | 2013 | 735 | 0.090 |
Why?
|
| Wind | 1 | 2010 | 6 | 0.090 |
Why?
|
| Antigens, Neoplasm | 4 | 2006 | 1580 | 0.090 |
Why?
|
| Gases | 1 | 2010 | 39 | 0.090 |
Why?
|
| Menopause | 1 | 2011 | 159 | 0.090 |
Why?
|
| Soot | 1 | 2010 | 17 | 0.090 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 1 | 2010 | 35 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2017 | 1320 | 0.090 |
Why?
|
| Hazardous Substances | 1 | 2010 | 25 | 0.090 |
Why?
|
| Sulfotransferases | 1 | 2011 | 42 | 0.090 |
Why?
|
| Environmental Pollution | 1 | 2010 | 18 | 0.090 |
Why?
|
| Gravitation | 1 | 2010 | 26 | 0.090 |
Why?
|
| Cities | 1 | 2010 | 57 | 0.090 |
Why?
|
| Heart Rate | 1 | 2014 | 742 | 0.090 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 114 | 0.090 |
Why?
|
| United Kingdom | 2 | 2024 | 287 | 0.090 |
Why?
|
| Fires | 1 | 2010 | 22 | 0.090 |
Why?
|
| Biosynthetic Pathways | 1 | 2010 | 48 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4481 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 223 | 0.090 |
Why?
|
| Smoke | 1 | 2010 | 61 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2013 | 823 | 0.090 |
Why?
|
| Self Report | 1 | 2015 | 797 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2020 | 3563 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2016 | 4061 | 0.090 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2010 | 115 | 0.090 |
Why?
|
| Anemia | 1 | 2016 | 728 | 0.090 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2010 | 152 | 0.090 |
Why?
|
| Dietary Supplements | 1 | 2014 | 555 | 0.090 |
Why?
|
| Chromosome Fragile Sites | 1 | 2010 | 38 | 0.090 |
Why?
|
| Histone Deacetylase 1 | 1 | 2010 | 62 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2020 | 657 | 0.090 |
Why?
|
| Equilin | 1 | 2009 | 5 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2010 | 188 | 0.090 |
Why?
|
| Platinum Compounds | 3 | 2017 | 129 | 0.090 |
Why?
|
| Estrone | 1 | 2009 | 32 | 0.090 |
Why?
|
| Lymphokines | 1 | 2010 | 309 | 0.090 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2009 | 32 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2009 | 22 | 0.080 |
Why?
|
| Hydatidiform Mole | 2 | 1999 | 39 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2013 | 667 | 0.080 |
Why?
|
| Osteoblasts | 1 | 2012 | 398 | 0.080 |
Why?
|
| PAX2 Transcription Factor | 1 | 2009 | 37 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 5 | 2019 | 5758 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2021 | 2416 | 0.080 |
Why?
|
| Binding Sites | 2 | 2010 | 2247 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 95 | 0.080 |
Why?
|
| Kidney | 1 | 2018 | 2110 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2010 | 329 | 0.080 |
Why?
|
| Social Class | 1 | 2011 | 324 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1577 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2011 | 268 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 7274 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 1269 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2013 | 2312 | 0.080 |
Why?
|
| Molecular Sequence Data | 4 | 2017 | 6641 | 0.080 |
Why?
|
| Radiation Oncology | 1 | 2014 | 558 | 0.080 |
Why?
|
| Antibodies | 2 | 2009 | 805 | 0.080 |
Why?
|
| Area Under Curve | 4 | 2012 | 729 | 0.080 |
Why?
|
| Peptide Library | 2 | 2006 | 148 | 0.080 |
Why?
|
| Sperm Retrieval | 1 | 2008 | 9 | 0.080 |
Why?
|
| Ovum | 1 | 2008 | 36 | 0.080 |
Why?
|
| DNA Fingerprinting | 1 | 2008 | 180 | 0.080 |
Why?
|
| Subcellular Fractions | 1 | 2008 | 210 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 898 | 0.080 |
Why?
|
| Chromones | 1 | 2008 | 121 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 521 | 0.080 |
Why?
|
| Polysaccharides | 1 | 2009 | 194 | 0.080 |
Why?
|
| Geography | 2 | 2018 | 140 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 3846 | 0.070 |
Why?
|
| Data Collection | 1 | 2010 | 608 | 0.070 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2008 | 224 | 0.070 |
Why?
|
| Pregnancy Rate | 1 | 2008 | 61 | 0.070 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2021 | 266 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 4966 | 0.070 |
Why?
|
| Embryo Transfer | 1 | 2008 | 88 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 526 | 0.070 |
Why?
|
| Endocytosis | 1 | 2008 | 228 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2008 | 878 | 0.070 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2007 | 7 | 0.070 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2007 | 56 | 0.070 |
Why?
|
| Protein Prenylation | 1 | 2007 | 20 | 0.070 |
Why?
|
| Feasibility Studies | 3 | 2021 | 2353 | 0.070 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2023 | 162 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2018 | 1328 | 0.070 |
Why?
|
| Leishmania major | 1 | 2007 | 27 | 0.070 |
Why?
|
| Androstadienes | 1 | 2008 | 172 | 0.070 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2010 | 402 | 0.070 |
Why?
|
| Prolactin | 1 | 2007 | 169 | 0.070 |
Why?
|
| Aurora Kinases | 1 | 2007 | 193 | 0.070 |
Why?
|
| Proteomics | 2 | 2011 | 1425 | 0.070 |
Why?
|
| Genomic Imprinting | 1 | 2008 | 199 | 0.070 |
Why?
|
| Rabbits | 1 | 2008 | 1028 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2021 | 3530 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2010 | 1607 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2014 | 1043 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 1131 | 0.070 |
Why?
|
| Endoplasmic Reticulum | 1 | 2008 | 328 | 0.070 |
Why?
|
| Cyclin D3 | 1 | 2006 | 26 | 0.070 |
Why?
|
| Kallikreins | 2 | 2005 | 85 | 0.070 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2007 | 91 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1582 | 0.070 |
Why?
|
| Tuberous Sclerosis | 1 | 2008 | 145 | 0.070 |
Why?
|
| Morpholines | 1 | 2008 | 296 | 0.070 |
Why?
|
| Octoxynol | 1 | 2006 | 12 | 0.070 |
Why?
|
| Models, Economic | 2 | 2021 | 102 | 0.070 |
Why?
|
| Life Cycle Stages | 1 | 2006 | 26 | 0.070 |
Why?
|
| Anxiety | 1 | 2013 | 1239 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 5263 | 0.070 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 277 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 3324 | 0.070 |
Why?
|
| Aurora Kinase A | 1 | 2007 | 209 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 1118 | 0.070 |
Why?
|
| Protozoan Proteins | 1 | 2007 | 123 | 0.070 |
Why?
|
| Imatinib Mesylate | 3 | 2005 | 1691 | 0.060 |
Why?
|
| Immunoblotting | 3 | 2017 | 888 | 0.060 |
Why?
|
| Base Pair Mismatch | 1 | 2005 | 82 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2007 | 318 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 5593 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 1435 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2008 | 1694 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 126 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1456 | 0.060 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2005 | 35 | 0.060 |
Why?
|
| Glycosylation | 1 | 2006 | 230 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2007 | 313 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 324 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2007 | 4552 | 0.060 |
Why?
|
| RNA Interference | 2 | 2007 | 1383 | 0.060 |
Why?
|
| Face | 2 | 2000 | 252 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2018 | 1709 | 0.060 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2005 | 63 | 0.060 |
Why?
|
| Genome, Human | 2 | 2010 | 1897 | 0.060 |
Why?
|
| Menstruation Disturbances | 1 | 2005 | 22 | 0.060 |
Why?
|
| Biopsy | 2 | 2014 | 3485 | 0.060 |
Why?
|
| Age Distribution | 2 | 2004 | 726 | 0.060 |
Why?
|
| DNA | 1 | 2013 | 3036 | 0.060 |
Why?
|
| Prevalence | 3 | 2007 | 3410 | 0.060 |
Why?
|
| Motor Activity | 1 | 2008 | 699 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2006 | 2308 | 0.060 |
Why?
|
| Organoplatinum Compounds | 1 | 2007 | 704 | 0.060 |
Why?
|
| Benzamides | 3 | 2005 | 1879 | 0.060 |
Why?
|
| Corrosion | 1 | 2024 | 2 | 0.060 |
Why?
|
| Perioperative Care | 2 | 2019 | 446 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 2636 | 0.060 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 107 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2018 | 666 | 0.060 |
Why?
|
| Porosity | 1 | 2024 | 59 | 0.060 |
Why?
|
| Cadherins | 1 | 2007 | 654 | 0.060 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2004 | 82 | 0.060 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2005 | 73 | 0.060 |
Why?
|
| Brazil | 1 | 2024 | 169 | 0.060 |
Why?
|
| Cluster Analysis | 3 | 2015 | 1074 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 223 | 0.060 |
Why?
|
| Linear Models | 2 | 2019 | 1093 | 0.060 |
Why?
|
| Materials Testing | 1 | 2024 | 119 | 0.060 |
Why?
|
| Adipocytes | 2 | 2016 | 294 | 0.060 |
Why?
|
| Phosphatidate Phosphatase | 1 | 2003 | 17 | 0.060 |
Why?
|
| Mexico | 1 | 2024 | 275 | 0.060 |
Why?
|
| DNA Replication | 1 | 2007 | 768 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2018 | 238 | 0.060 |
Why?
|
| Gene Regulatory Networks | 2 | 2019 | 678 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2004 | 191 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2015 | 264 | 0.050 |
Why?
|
| Papillomavirus Vaccines | 1 | 2006 | 197 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2012 | 2359 | 0.050 |
Why?
|
| Orgasm | 1 | 2022 | 12 | 0.050 |
Why?
|
| Decision Making | 3 | 2021 | 1252 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 2570 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2005 | 644 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2005 | 506 | 0.050 |
Why?
|
| Viral Vaccines | 1 | 2006 | 363 | 0.050 |
Why?
|
| Dantrolene | 1 | 2022 | 9 | 0.050 |
Why?
|
| Medical Records | 1 | 2004 | 441 | 0.050 |
Why?
|
| Bevacizumab | 2 | 2019 | 967 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 808 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 2903 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2016 | 1247 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 1557 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 7089 | 0.050 |
Why?
|
| Microsurgery | 1 | 1984 | 235 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2004 | 748 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2006 | 636 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2016 | 1071 | 0.050 |
Why?
|
| Advance Directives | 1 | 2023 | 89 | 0.050 |
Why?
|
| Esthetics | 1 | 2022 | 116 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2017 | 395 | 0.050 |
Why?
|
| Calibration | 2 | 2014 | 346 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 1661 | 0.050 |
Why?
|
| Surgery, Plastic | 1 | 1985 | 153 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2010 | 1326 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 1029 | 0.050 |
Why?
|
| RNA | 2 | 2004 | 1062 | 0.050 |
Why?
|
| Prostheses and Implants | 1 | 2024 | 294 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2004 | 338 | 0.050 |
Why?
|
| Hypertension | 2 | 2014 | 1593 | 0.050 |
Why?
|
| Lasers | 1 | 2022 | 234 | 0.050 |
Why?
|
| Splenectomy | 3 | 2020 | 168 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7899 | 0.050 |
Why?
|
| Length of Stay | 2 | 2019 | 2006 | 0.050 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2004 | 242 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 322 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2004 | 693 | 0.050 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 85 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 4831 | 0.050 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2001 | 108 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2022 | 367 | 0.050 |
Why?
|
| Wounds and Injuries | 1 | 1984 | 437 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 74 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 570 | 0.050 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2020 | 51 | 0.040 |
Why?
|
| Biological Specimen Banks | 2 | 2011 | 75 | 0.040 |
Why?
|
| Immunity | 1 | 2023 | 353 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 67 | 0.040 |
Why?
|
| Ostomy | 1 | 2020 | 19 | 0.040 |
Why?
|
| Protein Array Analysis | 2 | 2019 | 503 | 0.040 |
Why?
|
| NEDD8 Protein | 1 | 2020 | 23 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2021 | 220 | 0.040 |
Why?
|
| Pain | 1 | 2008 | 1694 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 84 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2024 | 889 | 0.040 |
Why?
|
| Immunotherapy, Active | 1 | 2000 | 49 | 0.040 |
Why?
|
| Polymers | 1 | 2021 | 219 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2007 | 631 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2021 | 1184 | 0.040 |
Why?
|
| Lactoferrin | 1 | 2020 | 87 | 0.040 |
Why?
|
| Pregnancy Outcome | 2 | 2002 | 684 | 0.040 |
Why?
|
| Global Health | 2 | 2015 | 692 | 0.040 |
Why?
|
| Tissue Expansion | 1 | 2000 | 71 | 0.040 |
Why?
|
| Corrosion Casting | 1 | 1999 | 5 | 0.040 |
Why?
|
| Deductibles and Coinsurance | 1 | 2019 | 10 | 0.040 |
Why?
|
| Cicatrix | 2 | 2000 | 187 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2020 | 354 | 0.040 |
Why?
|
| Machine Learning | 1 | 2022 | 361 | 0.040 |
Why?
|
| Patient Participation | 1 | 2023 | 453 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2024 | 965 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2024 | 765 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2017 | 2258 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2019 | 291 | 0.040 |
Why?
|
| Hospitals, County | 1 | 2018 | 32 | 0.040 |
Why?
|
| Diaphragm | 1 | 2020 | 187 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 3022 | 0.040 |
Why?
|
| Capillaries | 1 | 1999 | 98 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 377 | 0.040 |
Why?
|
| Hydro-Lyases | 1 | 2018 | 14 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 2019 | 116 | 0.040 |
Why?
|
| Glycogen | 1 | 2018 | 82 | 0.040 |
Why?
|
| Arteries | 1 | 2000 | 291 | 0.040 |
Why?
|
| Thyroid Neoplasms | 2 | 2012 | 1894 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 149 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1032 | 0.040 |
Why?
|
| Trophoblasts | 1 | 1999 | 150 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2019 | 166 | 0.040 |
Why?
|
| Dosage Compensation, Genetic | 1 | 1998 | 76 | 0.040 |
Why?
|
| Microcirculation | 1 | 1999 | 190 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2021 | 490 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 120 | 0.040 |
Why?
|
| Frozen Sections | 1 | 2018 | 113 | 0.040 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 1114 | 0.040 |
Why?
|
| Smoking | 1 | 2007 | 2555 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 1433 | 0.040 |
Why?
|
| Graft Survival | 1 | 2001 | 1084 | 0.040 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1379 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 402 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2019 | 323 | 0.040 |
Why?
|
| Cell Division | 3 | 2010 | 2647 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2021 | 509 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 600 | 0.040 |
Why?
|
| Pyrroles | 1 | 2021 | 587 | 0.040 |
Why?
|
| X Chromosome | 1 | 1998 | 398 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 5053 | 0.040 |
Why?
|
| Reproductive Health Services | 1 | 2016 | 19 | 0.030 |
Why?
|
| Lymph Nodes | 2 | 2020 | 3083 | 0.030 |
Why?
|
| Leuprolide | 1 | 2017 | 66 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2016 | 25 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 259 | 0.030 |
Why?
|
| Comorbidity | 2 | 2017 | 2393 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 1135 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 901 | 0.030 |
Why?
|
| Marital Status | 1 | 2016 | 92 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2005 | 2374 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 91 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2016 | 73 | 0.030 |
Why?
|
| Uterus | 1 | 2021 | 798 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 622 | 0.030 |
Why?
|
| Metabolomics | 1 | 2020 | 504 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2397 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2024 | 1208 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2018 | 140 | 0.030 |
Why?
|
| Nuchal Cord | 1 | 2015 | 3 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 1999 | 342 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 178 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4498 | 0.030 |
Why?
|
| Intestines | 1 | 2020 | 732 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2016 | 165 | 0.030 |
Why?
|
| Pancreatectomy | 1 | 2020 | 696 | 0.030 |
Why?
|
| Osteocytes | 1 | 2015 | 35 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2015 | 85 | 0.030 |
Why?
|
| Laparotomy | 1 | 2017 | 249 | 0.030 |
Why?
|
| Caloric Restriction | 1 | 2016 | 88 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 392 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2015 | 139 | 0.030 |
Why?
|
| Transcriptome | 2 | 2014 | 1960 | 0.030 |
Why?
|
| Poverty | 1 | 2018 | 486 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 3466 | 0.030 |
Why?
|
| Sigmoidoscopy | 1 | 2014 | 49 | 0.030 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2014 | 33 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 772 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 731 | 0.030 |
Why?
|
| Penetrance | 1 | 2015 | 134 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2000 | 616 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 174 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 2015 | 244 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2018 | 758 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2014 | 88 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 99 | 0.030 |
Why?
|
| Automation | 1 | 2014 | 154 | 0.030 |
Why?
|
| Antigens | 2 | 2005 | 280 | 0.030 |
Why?
|
| Sarcoma | 1 | 2005 | 1851 | 0.030 |
Why?
|
| Folic Acid Deficiency | 1 | 2014 | 55 | 0.030 |
Why?
|
| Chemokines | 1 | 2015 | 290 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 1016 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 400 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 137 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2016 | 549 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 485 | 0.030 |
Why?
|
| Probability | 2 | 2009 | 886 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 147 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 626 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 360 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 626 | 0.030 |
Why?
|
| Precipitin Tests | 2 | 2004 | 349 | 0.030 |
Why?
|
| Religion | 1 | 2014 | 95 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 508 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 1090 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2016 | 379 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2019 | 1342 | 0.030 |
Why?
|
| Lysine | 1 | 2015 | 426 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2020 | 1015 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 1237 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 4103 | 0.030 |
Why?
|
| Mucositis | 1 | 2014 | 149 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2019 | 1260 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 993 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1097 | 0.030 |
Why?
|
| 3' Flanking Region | 1 | 2012 | 8 | 0.030 |
Why?
|
| 5' Flanking Region | 1 | 2012 | 21 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 815 | 0.030 |
Why?
|
| Standard of Care | 1 | 2015 | 277 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 495 | 0.030 |
Why?
|
| Introns | 1 | 2014 | 457 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2000 | 1858 | 0.030 |
Why?
|
| HSP47 Heat-Shock Proteins | 1 | 2012 | 5 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 809 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 1998 | 854 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 757 | 0.030 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2012 | 11 | 0.030 |
Why?
|
| Peptides | 2 | 2011 | 1503 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1640 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 419 | 0.030 |
Why?
|
| Reference Standards | 1 | 2013 | 367 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 84 | 0.030 |
Why?
|
| Burns | 2 | 2000 | 130 | 0.030 |
Why?
|
| Quality Control | 1 | 2013 | 461 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2016 | 709 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2012 | 202 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 433 | 0.020 |
Why?
|
| Classification | 1 | 2011 | 39 | 0.020 |
Why?
|
| Systems Biology | 1 | 2012 | 115 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 1016 | 0.020 |
Why?
|
| Computers | 1 | 2012 | 132 | 0.020 |
Why?
|
| Smad6 Protein | 1 | 2011 | 13 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2020 | 2373 | 0.020 |
Why?
|
| raf Kinases | 1 | 2011 | 80 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 113 | 0.020 |
Why?
|
| Subcutaneous Fat | 1 | 2011 | 65 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 264 | 0.020 |
Why?
|
| Prealbumin | 1 | 2011 | 39 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 95 | 0.020 |
Why?
|
| Exons | 1 | 2015 | 1390 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2011 | 206 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2011 | 100 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 426 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2010 | 50 | 0.020 |
Why?
|
| Cancer Survivors | 1 | 2018 | 743 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2010 | 110 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2012 | 232 | 0.020 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2011 | 188 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 511 | 0.020 |
Why?
|
| Mental Health | 1 | 2013 | 416 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2012 | 327 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2010 | 129 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 1436 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 533 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 122 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 202 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2010 | 231 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 254 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1052 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 1028 | 0.020 |
Why?
|
| G2 Phase | 1 | 2010 | 218 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 632 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 630 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 449 | 0.020 |
Why?
|
| Collagen | 1 | 2012 | 721 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 125 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 2187 | 0.020 |
Why?
|
| Protein Binding | 1 | 2015 | 3477 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 5727 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 514 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1852 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 855 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 990 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2009 | 474 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2009 | 274 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2007 | 47 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 483 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2012 | 677 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2007 | 74 | 0.020 |
Why?
|
| Spodoptera | 1 | 2007 | 81 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2005 | 7047 | 0.020 |
Why?
|
| Protein Methyltransferases | 1 | 2007 | 46 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2010 | 579 | 0.020 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2007 | 53 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 1683 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 1462 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 4330 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2008 | 338 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 2192 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 17096 | 0.020 |
Why?
|
| Metalloendopeptidases | 1 | 2007 | 176 | 0.020 |
Why?
|
| Diet | 1 | 2014 | 1474 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 1826 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2006 | 35 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 2028 | 0.020 |
Why?
|
| Pertussis Toxin | 1 | 2006 | 62 | 0.020 |
Why?
|
| Alopecia | 1 | 2006 | 124 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2007 | 350 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2006 | 67 | 0.020 |
Why?
|
| Propionates | 1 | 2006 | 73 | 0.020 |
Why?
|
| Shoulder | 1 | 1986 | 46 | 0.020 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2006 | 89 | 0.020 |
Why?
|
| Claudin-3 | 1 | 2005 | 6 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 591 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 4020 | 0.020 |
Why?
|
| Cystadenoma | 1 | 2005 | 28 | 0.020 |
Why?
|
| Endopeptidases | 1 | 2007 | 229 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 1484 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2006 | 81 | 0.020 |
Why?
|
| CpG Islands | 1 | 2008 | 671 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 3037 | 0.020 |
Why?
|
| Sialoglycoproteins | 1 | 2005 | 151 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1956 | 0.020 |
Why?
|
| Osteopontin | 1 | 2005 | 145 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2005 | 323 | 0.020 |
Why?
|
| Vomiting | 1 | 2006 | 361 | 0.020 |
Why?
|
| CA-19-9 Antigen | 1 | 2005 | 155 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 287 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2005 | 158 | 0.010 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2004 | 75 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1588 | 0.010 |
Why?
|
| Platinum | 1 | 2005 | 142 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2004 | 327 | 0.010 |
Why?
|
| Nausea | 1 | 2006 | 539 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2004 | 49 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 1415 | 0.010 |
Why?
|
| Cell Polarity | 1 | 2005 | 211 | 0.010 |
Why?
|
| Lovastatin | 1 | 2004 | 56 | 0.010 |
Why?
|
| Mucins | 1 | 2005 | 289 | 0.010 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2015 | 2178 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2007 | 820 | 0.010 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2003 | 34 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 397 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2007 | 592 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 1468 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 271 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4366 | 0.010 |
Why?
|
| Scalp | 1 | 1985 | 155 | 0.010 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2007 | 468 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 600 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 369 | 0.010 |
Why?
|
| S Phase | 1 | 2004 | 285 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2003 | 237 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2004 | 354 | 0.010 |
Why?
|
| Emergencies | 1 | 1984 | 224 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 511 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 305 | 0.010 |
Why?
|
| Immune System | 1 | 2004 | 275 | 0.010 |
Why?
|
| Mothers | 1 | 2006 | 415 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 298 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 722 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 701 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2004 | 722 | 0.010 |
Why?
|
| Transplantation, Autologous | 2 | 2005 | 2067 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 1106 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 936 | 0.010 |
Why?
|
| Recurrence | 1 | 2010 | 4877 | 0.010 |
Why?
|
| DNA Damage | 1 | 2010 | 1991 | 0.010 |
Why?
|
| Dermis | 1 | 2001 | 63 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2005 | 775 | 0.010 |
Why?
|
| Lacerations | 1 | 2001 | 35 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 686 | 0.010 |
Why?
|
| Epithelium | 1 | 2003 | 779 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 1406 | 0.010 |
Why?
|
| Kinetics | 1 | 2004 | 2215 | 0.010 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2002 | 236 | 0.010 |
Why?
|
| Transplantation, Homologous | 2 | 2005 | 3047 | 0.010 |
Why?
|
| Drosophila | 1 | 2005 | 899 | 0.010 |
Why?
|
| Telomerase | 1 | 2003 | 545 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2001 | 369 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 1739 | 0.010 |
Why?
|
| Thiazoles | 1 | 2004 | 727 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2004 | 2454 | 0.010 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 1999 | 32 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 1577 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 3245 | 0.010 |
Why?
|
| Proestrus | 1 | 1978 | 4 | 0.010 |
Why?
|
| Estrus | 1 | 1978 | 30 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 1541 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1474 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2002 | 799 | 0.010 |
Why?
|
| Neck | 1 | 2000 | 395 | 0.010 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1978 | 168 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 2514 | 0.010 |
Why?
|
| Hypothalamus | 1 | 1978 | 271 | 0.010 |
Why?
|
| Melanoma | 1 | 2012 | 5597 | 0.010 |
Why?
|
| Child | 2 | 2006 | 30590 | 0.010 |
Why?
|
| Schistosomiasis | 2 | 1963 | 65 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 7784 | 0.010 |
Why?
|
| Contracture | 1 | 1985 | 35 | 0.000 |
Why?
|
| Schistosomiasis japonica | 1 | 1963 | 6 | 0.000 |
Why?
|
| Varicose Veins | 1 | 1963 | 30 | 0.000 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1963 | 95 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1963 | 453 | 0.000 |
Why?
|
| Stomach | 1 | 1963 | 400 | 0.000 |
Why?
|
| Castration | 1 | 1978 | 122 | 0.000 |
Why?
|
| Pineal Gland | 1 | 1978 | 42 | 0.000 |
Why?
|
| Luteinizing Hormone | 1 | 1978 | 165 | 0.000 |
Why?
|
| Pituitary Gland | 1 | 1978 | 151 | 0.000 |
Why?
|
| Feedback | 1 | 1978 | 225 | 0.000 |
Why?
|
| Liver Cirrhosis | 1 | 1963 | 1046 | 0.000 |
Why?
|
| Methods | 1 | 1973 | 223 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1973 | 252 | 0.000 |
Why?
|
| Wound Healing | 1 | 1973 | 746 | 0.000 |
Why?
|
| China | 1 | 1963 | 636 | 0.000 |
Why?
|